Icahn School of Medicine at Mount Sinai (ISMMS)

The Icahn School of Medicine at Mount Sinai (ISMMS), formerly Mount Sinai School of Medicine, is a medical school in New York City, New York.

Could artificial intelligence predict which viruses could infect humans, which animals host them, and where they could emerge from?

A new target for a universal influenza vaccine

Putting cancer cells to sleep to prevent tumor metastasis

Can wearable devices detect Covid-19 symptoms earlier and predict diagnosis?

3D printing of human tissue and eventually entire organs just got 10-50 times faster

Ketamine does help individuals with chronic post-traumatic stress disorder (PTSD)

Turning tumors into cancer vaccine factories

Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body. The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head

Turning tumors into cancer vaccine factories

New genetic barcoding technology identifies critical cancer immunity genes

Novel gene editing technique reveals cancer weakness in the immune system and opens possibilities to identify disease-causing genes and new drug targets Scientists at Mount Sinai have developed a novel technology for simultaneously analyzing the functions of hundreds of genes with resolution reaching the single cell level. The technology relies on a barcoding approach using

New genetic barcoding technology identifies critical cancer immunity genes

Found: A marker that can indicate whether a breast cancer patient will develop a reoccurrence of lethal metastatic cancer

For the first time ever, Mount Sinai researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a reoccurrence of lethal, metastatic cancer, according to a clinical study published in Breast Cancer Research in October. The researchers found that when cells from a breast cancer patient’s original tumor metastasized into

Found: A marker that can indicate whether a breast cancer patient will develop a reoccurrence of lethal metastatic cancer

Sperm concentration in Western men has declined more than 50 percent in less than 40 years

Meta-analysis finds that among men from North America, Europe and Australia, sperm concentration has declined more than 50 percent in less than 40 years, pointing to impaired male health and decreasing fertility In the first systematic review and meta-analysis of trends in sperm count, researchers from the Hebrew University-Hadassah Braun School of Public Health and

Sperm concentration in Western men has declined more than 50 percent in less than 40 years

Almost 200 Years Later, Are We Living in the Final Days of the Stethoscope

“Certainly the stage is set for disruption” An editorial in this month’s edition of Global Heart (the journal of the World Heart Federation) asks ‘are we living in the final days of the stethoscope’—a question being asked due to the rapid advent of point-of-care ultrasound devices, that are becoming increasingly accurate, smaller to the point

Almost 200 Years Later, Are We Living in the Final Days of the Stethoscope

Vitamin E May Delay Decline in Mild-to-Moderate Alzheimer’s Disease

Study Shows Benefit in Activities of Daily Living and Savings in Caregiver Time with Vitamin E Difficulty with activities of daily living often affect Alzheimer’s patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million

Vitamin E May Delay Decline in Mild-to-Moderate Alzheimer’s Disease

The Latest Bing News on:

Icahn School of Medicine at Mount Sinai (ISMMS) Research

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
Continued KidneyIntelX testing volume growth Over 3,000 KidneyIntelX risk scores generated for Mount Sinai Health System patients and over 300 at Wake Forest Baptist Health 33 state Medicaid ...
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
LONDON and SALT LAKE CITY, June 30, Jun 30, 2022 (GLOBE NEWSWIRE via COMTEX) -- LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc ...
Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions ... of ...
Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions ... of ...
Microbiology Virtual Week 2021
Labroots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 7th Annual ...

The Latest Google Headlines on:

Icahn School of Medicine at Mount Sinai (ISMMS) Research

The Latest Bing News on:

Icahn School of Medicine at Mount Sinai (ISMMS) Discovery

Phenotypic screen with deep learning finds cardioprotective molecules
so here we allowed a deep learning algorithm to guide us early in the discovery process,” explains lead author Mohammad Mandegar from Tenaya Therapeutics. The investigators screened a library of ...
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
Continued KidneyIntelX testing volume growth Over 3,000 KidneyIntelX risk scores generated for Mount Sinai Health System patients and over 300 at Wake Forest Baptist Health 33 state Medicaid ...
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
LONDON and SALT LAKE CITY, June 30, Jun 30, 2022 (GLOBE NEWSWIRE via COMTEX) -- LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc ...
Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions ... of ...
Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions ... of ...